Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a ligand for in vivo imaging of mutant huntingtin in Huntington’s disease

2 Feb 2022

Abstract excerpt

Huntington’s disease (HD) is a dominantly inherited neurodegenerative disorder caused by a CAG trinucleotide expansion in the huntingtin ( HTT ) gene that encodes the pathologic mutant HTT (mHTT) protein with an expanded polyglutamine (polyQ) tract. Whereas several therapeutic programs targeting mHTT expression have advanced to clinical evaluation, methods to visualize mHTT protein species in the living brain are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Neurodegenerative Diseases
Share to Mitochondrial Function and Pathology
Share to Neurological disorders and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35108063
DOI: 10.1126/scitranslmed.abm3682

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a ligand for in vivo imaging of mutant huntingtin in Huntington’s diseasePMID 35108063Read ↗

A novel imaging ligand as a biomarker for mutant huntingtin-lowering in Huntington’s diseaseSemantic proximity Read ↗

In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using11C-CHDI-180R PET in a Nonhuman Primate Model of Huntington DiseaseSemantic proximity Read ↗

Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidatesSemantic proximity Read ↗

In Vivo PET Imaging of [18F]CHDI-385, a Radioligand for Mutant Huntingtin Aggregates in a Mouse Model of Huntington Disease.Semantic proximity Read ↗

Preclinical evaluation of [ <sup>11</sup> C]CHDI-009R for quantification of mutant huntingtin aggregatesSemantic proximity Read ↗

Preclinical evaluation of [11C]CHDI-009R for quantification of mutant huntingtin aggregatesSemantic proximity Read ↗

Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand.Semantic proximity Read ↗

Longitudinal Preclinical Evaluation of the Novel Radioligand [11C]CHDI-626 for PET Imaging of Mutant Huntingtin Aggregates in Huntington’s DiseaseSemantic proximity Read ↗

PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington's disease.Semantic proximity Read ↗

Preclinical evaluation of the novel [18F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease.Semantic proximity Read ↗

PET Ligands for Imaging Mutant Huntingtin Aggregates: A Case Study in Non-For-Profit Scientific Management.Semantic proximity Read ↗

Preclinical evaluation of the novel [ <sup>18</sup> F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.